Individual Variation in Long-Term Distress After Breast Cancer Surgery

2003 ◽  
Author(s):  
Keith Millar
2019 ◽  
Vol 45 (10) ◽  
pp. 1827-1834 ◽  
Author(s):  
Luca Sorrentino ◽  
Lea Regolo ◽  
Elisabetta Scoccia ◽  
Gianfranco Petrolo ◽  
Daniela Bossi ◽  
...  

2020 ◽  
Vol 46 (1) ◽  
pp. 3-12 ◽  
Author(s):  
Nasir Hussain ◽  
Richard Brull ◽  
Jordan Noble ◽  
Tristan Weaver ◽  
Michael Essandoh ◽  
...  

The novel erector spinae plane block (ESPB) has been reported to provide important postoperative analgesic benefits following a variety of truncal and abdominal surgical procedures. However, evidence of its analgesic efficacy following breast cancer surgery, compared with parenteral analgesia, is unclear. This meta-analysis evaluates the analgesic benefits of adding ESPB to parenteral analgesia following breast cancer surgery.Databases were searched for breast tumor resection trials comparing ESPB to parenteral analgesia. The two co-primary outcomes examined were 24-hour postoperative oral morphine equivalent consumption and area-under-curve of rest pain scores. We considered reductions equivalent to 3.3 cm.h and 30 mg oral morphine in the first 24 hours postoperatively for the two co-primary outcomes, respectively, to be clinically important. We also assessed opioid-related side effects and long-term outcomes, including health-related quality of life, persistent postsurgical pain and opioid dependence. Results were pooled using random effects modeling.Twelve trials (699 patients) were analyzed. Moderate quality evidence suggested that ESPB decreased 24-hour morphine consumption and area-under-curve of rest pain by a mean difference (95% CI) of −17.60 mg (−24.27 to −10.93) and -2.74 cm.h (−3.09 to −2.39), respectively; but these differences were not clinically important. High-quality evidence suggested that ESPB decreased opioid-related side effects compared with parenteral analgesia by an OR (95% CI) of 0.43 (0.28 to 0.66). None of the studies evaluated long-term block benefits.Adding ESPB to parenteral analgesia provides statistically significant but clinically unimportant short-term benefits following breast cancer surgery. Current evidence does not support routine use of ESPB. Given the very modest short-term benefits and risk of complications, the block should be considered on a case-by-case basis.


2020 ◽  
Vol 46 (2) ◽  
pp. e52-e53
Author(s):  
Pasupathy Kiruparan ◽  
Mariana Matias ◽  
Rachel Moir ◽  
Debasish Debnath ◽  
David Archampong

2005 ◽  
Vol 75 (8) ◽  
pp. 625-630 ◽  
Author(s):  
Katrina Spilsbury ◽  
James B. Semmens ◽  
Christobel M. Saunders ◽  
C. D. J. Holman

Sign in / Sign up

Export Citation Format

Share Document